Your session is about to expire
← Back to Search
Venetoclax + Ibrutinib for Chronic Lymphocytic Leukemia
Study Summary
This trial is testing how well venetoclax and ibrutinib work to treat people with CLL who have developed genetic mutations after being treated with ibrutinib. Venetoclax and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What risks could arise from taking Venetoclax?
"The safety of Venetoclax was rated a 2 as this is a Phase 2 clinical trial, indicating there has been some evidence collected on its safety but not yet efficacy."
Are there additional studies that have been conducted on Venetoclax?
"Presently, 343 studies are in progress focusing on Venetoclax. 45 of these trials have entered the third phase and most of them are located in Edmonton, Alberta. However, there is a total of 11,699 sites conducting research with this drug."
Are there any slots remaining to participate in this medical investigation?
"This medical research project is no longer recruiting participants, as the latest update to this trial was recorded on April 8th 2022. If you're looking for similar studies, 1522 clinical trials involving ibrutinib are actively enrolling patients and 343 Venetoclax-centred investigations are in need of volunteers."
What has been the primary application for Venetoclax?
"Venetoclax has been found to be a successful treatment for waldenstrom macroglobulinemia, small lymphocytic lymphoma and chronic lymphocytic leukemia (CLL)."
What is the current number of participants in this experiment?
"At this time, recruitment for the trial has ceased. Initially posted on March 26th 2019, and last amended April 8th 2022; if you are looking to join an alternative study there are 1522 ibrutinib trials currently recruiting and 343 Venetoclax investigations accepting participants."
Share this study with friends
Copy Link
Messenger